Search Site

Fabio M. Iwamoto, MD

  • Assistant Professor of Neurology
  • Deputy Director, Division of Neuro-Oncology
Fabio M. Iwamoto, MD

Dr. Iwamoto is a neuro-oncologist whose previous training includes a neurology residency at NewYork-Presbyterian/Weill Cornell Medical Center and a neuro-oncology fellowship at Memorial Sloan-Kettering Cancer Center. For over three years, Dr. Iwamoto was an attending physician and an investigator at the Neuro-oncology Branch, a trans-institute branch of the National Cancer Institute and National Institute of Neurological Disorders and Stroke, in Bethesda, MD. At the intramural NIH, Dr. Iwamoto was a principal investigator in early phase clinical trials for brain tumors and worked with laboratory and computational scientists on several translational projects in brain tumors.

Dr. Iwamoto was recruited to Columbia University as the Deputy Director of the Neuro-oncology Division and is actively developing the clinical and translational research components of this program. He is an expert in the diagnosis, management, and treatment of brain and spinal cord tumors as well as neurological complications of cancer.

Departmental Appointments

  • Department of Neurology
    Division of Neuro-oncology

Education & Training

  • Universidad Federal Do Parana
  • Residency: Memorial Sloan-Kettering Cancer Center
  • Residency: NewYork-Presbyterian Hospital/Weill Cornell Medical Center

Centers/Institutes/Programs

  • Herbert Irving Comprehensive Cancer Center

NIH Grants

  • A PHASE 1/2 STUDY OF SL-701, A SUBCUTANEOUSLY INJECTED MULTIVALENT GLIOMA- ASSOCIATED ANTIGEN VACCINE, IN ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

    Dec 18 2014 - Dec 18 2019

    PHASE II STUDY OF BEVACIZUMAB AND TEMOZOLOMIDE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (P&S Industry Clinical Trial)

    Oct 20 2014 - Oct 20 2019

    A PHASE I/II TRIAL OF EVEROLIMUS (RAD001) AND SORAFENIB IN PATIENTS WITH HIGH-GRADE GLIOMAS (P&S Industry Clinical Trial)

    Jun 17 2013 - Jun 17 2018

    PHASE II TRIAL OF BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMAS (P&S Industry Clinical Trial)

    Mar 22 2013 - Mar 22 2018

    A PHASE III CLINICAL TRIAL EVALUATING DCVAX-L, AUTOLOGOUS DENDRITIC CELLS PULSED WITH TUMOR LYSATE ANTIGEN FOR THE TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) (P&S Industry Clinical Trial)

    Dec 11 2012 - Dec 11 2017

    RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)

    Jan 1 2009 - Dec 31 2014

    RADIATION THERAPY ONCOLOGY GROUP (RTOG) (Federal Gov)

    Jan 1 2009 - Dec 31 2014